Humanized anti-cd200 antibodies and uses thereof
AssigneeAlexion Pharmaceuticals, Inc.
InventorsTaneisha Ann-Tanara MACK, Douglas L. SHERIDAN, Tadas PANAVAS
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200. Also provided are uses of these proteins in therapeutic applications, such as the treatment of cancer and in conjunction with organ transplantation. Also provided are nucleic acids encoding the heavy and/or light chain variable regions (or heavy and/or light chains) of the antibodies, vectors comprising the nucleic acids, and cells that produce the antibodies.
Claims28
An isolated humanized antibody which binds to human CD200 and comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:
- 20, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:
- 21, and wherein the antibody has at least one amino acid substitution in the heavy chain variable region at a position selected from the group consisting of:
- A97, M48, A9, V11, K12, V18, V20, R38, A40, P41, P43, R44, R67, V68, I70, R72, T174, A76, E82, S84, and R87, and/or at least one amino acid substitution in the light chain variable region at a position selected from the group consisting of:
- A84, S12, T69, F71, T72, Q79, P80, F83, and T85, wherein the numbering is according to the amino acid sequence in SEQ ID NO:
- 20 for the heavy chain variable region and SEQ ID NO:
- 21 for the light chain variable region.
3-4. (canceled)
An isolated antibody which binds to human CD200 and comprises heavy and light chain variable region sequences selected from the group consisting of:
- a) SEQ ID NOs:
- 107 and 108, respectively;
- b) SEQ ID NOs:
- 158 and 159, respectively;
- c) SEQ ID NOs:
- 149 and 150, respectively;
- d) SEQ ID NOs:
- 26 and 27, respectively;
- e) SEQ ID NOs:
- 29 and 30, respectively;
- f) SEQ ID NOs:
- 32 and 33, respectively;
- g) SEQ ID NOs:
- 35 and 36, respectively;
- h) SEQ ID NOs:
- 38 and 39, respectively;
- i) SEQ ID NOs:
- 41 and 42, respectively;
- j) SEQ ID NOs:
- 44 and 45, respectively;
- k) SEQ ID NOs:
- 47 and 48, respectively;
- l) SEQ ID NOs:
- 50 and 51, respectively;
- m) SEQ ID NOs:
- 53 and 54, respectively;
- n) SEQ ID NOs:
- 56 and 57, respectively;
- o) SEQ ID NOs:
- 59 and 60, respectively;
- p) SEQ ID NOs:
- 62 and 63, respectively;
- q) SEQ ID NOs:
- 65 and 66, respectively;
- r) SEQ ID NOs:
- 68 and 69, respectively;
- s) SEQ ID NOs:
- 71 and 72, respectively;
- t) SEQ ID NOs:
- 74 and 75, respectively;
- u) SEQ ID NOs:
- 77 and 78, respectively;
- v) SEQ ID NOs:
- 80 and 81, respectively;
- w) SEQ ID NOs:
- 83 and 84, respectively;
- x) SEQ ID NOs:
- 86 and 87, respectively;
- y) SEQ ID NOs:
- 89 and 90, respectively;
- z) SEQ ID NOs:
- 92 and 93, respectively;
- aa) SEQ ID NOs:
- 95 and 96, respectively;
- bb) SEQ ID NOs:
- 98 and 99, respectively;
- cc) SEQ ID NOs:
- 101 and 102, respectively;
- dd) SEQ ID NOs:
- 104 and 105, respectively;
- ee) SEQ ID NOs:
- 110 and 111, respectively;
- ff) SEQ ID NOs:
- 113 and 114, respectively;
- gg) SEQ ID NOs:
- 116 and 117, respectively;
- hh) SEQ ID NOs:
- 119 and 120, respectively;
- ii) SEQ ID NOs:
- 122 and 123, respectively;
- jj) SEQ ID NOs:
- 125 and 126, respectively;
- kk) SEQ ID NOs:
- 128 and 129, respectively;
- ll) SEQ ID NOs:
- 131 and 132, respectively;
- mm) SEQ ID NOs:
- 134 and 135, respectively;
- nn) SEQ ID NOs:
- 137 and 138, respectively;
- oo) SEQ ID NOs:
- 140 and 141, respectively;
- pp) SEQ ID NOs:
- 143 and 144, respectively;
- qq) SEQ ID NOs:
- 146 and 147, respectively;
- rr) SEQ ID NOs:
- 152 and 153, respectively;
- ss) SEQ ID NOs:
- 155 and 156, respectively;
- tt) SEQ ID NOs:
- 161 and 162, respectively;
- uu) SEQ ID NOs:
- 164 and 165, respectively;
- vv) SEQ ID NOs:
- 167 and 168, respectively;
- ww) SEQ ID NOs:
- 170 and 171, respectively;
- xx) SEQ ID NOs:
- 173 and 174, respectively;
- yy) SEQ ID NOs:
- 176 and 177, respectively;
- and
- zz) SEQ ID NOs:
- 179 and 180, respectively.
6-14. (canceled)
16-20. (canceled)
An isolated antibody which binds to human CD200 and comprises human and light chain sequences selected from the group consisting of:
- a. SEQ ID NOs:
- 185 and 186, respectively,
- b. SEQ ID NOs:
- 183 and 184, respectively, and
- c. SEQ ID NOs:
- 181 and 182, respectively.
(canceled)
33-46. (canceled)
(canceled)
50-57. (canceled)
(canceled)
Dependencies are inferred from the claim text.